The global Implantable Ocular Neurostimulator market size is predicted to grow from US$ 114 million in 2025 to US$ 282 million in 2031; it is expected to grow at a CAGR of 16.2% from 2025 to 2031.

An implantable ocular neurostimulator is a medical device that improves vision or treats eye diseases by electrically stimulating the ocular nerves. The device is usually surgically implanted in the eye or retinal area and uses electrical current to stimulate the optic nerve or related neural pathways to help restore visual function or relieve symptoms of eye diseases such as retinal degeneration, blindness or other visual impairments.

Implantable ocular neurostimulators can provide long-lasting therapeutic effects and are often used to treat irreversible visual damage or promote the reconstruction of the optic nerve.

Key Features

• Market growth from US$ 114 million in 2025 to US$ 282 million in 2031.
• CAGR of 16.2% from 2025 to 2031.
• Implantable devices aimed to improve vision and treat ocular diseases.

Segmentation by Type

• Retinal Nerve Stimulator
• Optic Nerve Stimulator

Segmentation by Application

• General Hospital
• Specialized Hospital

Market by Region

• Americas
• APAC
• Europe
• Middle East & Africa

Company's Coverage

• Bionic Sight
• Monash Vision Group
• Neuralink
• Precision Neuroscience
• Lambda Vision
• Chaomu Technology

Key Questions Addressed in this Report

• What is the 10-year outlook for the global Implantable Ocular Neurostimulator market?
• What factors are driving Implantable Ocular Neurostimulator market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Implantable Ocular Neurostimulator market opportunities vary by end market size?
• How does Implantable Ocular Neurostimulator break out by Type, by Application?